Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: Issues and potential complications

Journal of the American Osteopathic Association

Volumn 108, Issue 7, 2008, Pages 333-337

  Fine, Shari R ^a,c   Ginsberg, Phillip ^b  

^a Christ Hospital Jersey City   (United States)

^b ALBERT EINSTEIN MEDICAL CENTER   (United States)

^c UMDNJ School of Osteopathic Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; DILTIAZEM; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; NEUROLEPTIC AGENT; NIFEDIPINE; PLACEBO; SEDATIVE AGENT; SILDENAFIL; TADALAFIL; TAMSULOSIN; TERAZOSIN; VARDENAFIL; VASODILATOR AGENT;

AGING; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; ERECTILE DYSFUNCTION; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; HYPOVOLEMIA; LOWER URINARY TRACT SYMPTOM; ORTHOSTATIC HYPOTENSION; PREVALENCE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RECEPTOR BLOCKING; REVIEW; RHINITIS; RISK ASSESSMENT; SIDE EFFECT; VASODILATATION;

ADRENERGIC ALPHA-ANTAGONISTS; AGE FACTORS; AGED; AGING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; HYPOTENSION; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URINATION DISORDERS;

EID: 48249138056     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension [review]. Scand J Urol Nephrol. 1995;29:7-12.
2. Lepor H, Lowe FC. Evaluation and nonsurgical management of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED, eds. Campbell's Urol. 8th ed. Philadelphia, Pa: WB Saunders Co; 2002:1337-1378.
3. O'Leary MP. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications [review]. Urol. 2003;62(3 suppl 1):15-23. doi:10.1016/S0090-4295(03)00480-1.
4. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170(pt 1):530-547.
5. Oesterling JE. Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate Suppl. 1996;6:67-73.
6. National Diabetes Statistics. National Diabetes Information Clearinghouse Web site. Available at: http://www.diabetes.niddk.nih.gov/dm/pubs/statistics/ index.htm. Accessed June 16, 2008.
7. Older Americans and cardiovascular diseases. American Heart Association Web site. Available at: http://www.americanheart.org. Accessed June 16, 2008.
8. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The third national health and nutrition examination survey, 1988-1994. Diabetes Care. 1998;21:518-524. Available at: http://care.diabetesjournals.org/cgi/reprint/21/4/518. Accessed June 30, 2008.
9. Shibao C, Grijalva CG, Raj SR, Biaggioni I, Griffin MR. Orthostatic hypotension-related hospitalizations in the United States. Am J Med. 2007;120:975-980. doi:10.1016/j.amjmed.2007.05.009.
10. Low PA. Prevalence of orthostatic hypotension [review]. Clin Auton Res. 2008; 18(suppl 1):8-13. Published June 30, 2008. doi:10.1007/s10286- 007-1001-3.
11. Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther. 2005;30:173-178.
12. Kane RL, Ouslander JG, Abrass IP. Essentials of Clinical Geriatrics. New York, NY: McGraw-Hill Inc; 1994:197-213.
13. Shimada K, Kitazumi T, Ogura H, Sadakane N, Ozawa T. Differences in age-independent effects of blood pressure on baroreflex sensitivity between normal and hypertensive subjects. Clin Sci (Lond). 1986;70:489-494.
14. Shannon RP, Maher KA, Santinga JT, Royal HD, Wei JY. Comparison of differences in the hemodynamic response to passive postural stress in healthy subjects greater than 70 years and less than 30 years of age. Am J Cardiol. 1991;67:1110-1116.
15. James MA, Potter JF. Orthostatic blood pressure changes and arterial baroreflex sensitivity in elderly subjects. Age Ageing. 1999;28:522-530. Available at: http://ageing.oxfordjournals.org/cgi/reprint/28/6/522. Accessed July 3, 2008.
16. Mukai S, Gagnon M, Iloputaife I, Hamner JW, Lipsitz LA. Effect of systolic blood pressure and carotid stiffness on baroreflex gain in elderly subjects. J Gerontol A Biol Sci Med Sci. 2003;58:626-630.
17. Priebe HJ. The aged cardiovascular risk patient [review]. Br J Anaesth. 2000;85:763-778. Available at: http://bja.oxfordjournals.org/cgi/ content/full/85/5/763. Accessed July 3, 2008.
18. Tilvis RS, Hakala SM, Valvanne J, Erkinjuntti T. Postural hypotension and dizziness in a general aged population: a four-year follow-up of the Helsinki Aging Study. J Am Geriatr Soc. 1996;44:809-814.
19. Campbell AJ. Drug treatment as a cause of falls in old age. A review of the offending agents. Drugs Aging. 1991;1:289-302. doi:10.1016/S0090- 4295(98)00140-X.
20. 1A-adrenergic antagonist [review]. Urol. 1998;51:861-872.
21. 1D-subtype in filling symptoms and effects of aging on vascular expression [review]. BJU Int. 2000;85(suppl 2):6-11.
22. 1-adrenoreceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol. 1994;113:723-728. Available at: http://www.pubmedcentral. nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=7858860. Accessed June 30, 2008.
23. 1-adrenoreceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol. 1995;288:201-207.
24. de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol. 1998;33:481-488. doi:10.1159/000019639.
25. Hytrin [package insert]. North Chicago, Il: Abbott Laboratories; 2001.
26. Uroxatral [package insert]. New York, NY: Sanofi-Synthelabo; 2007.
27. Flomax [package insert]. Ridgefield, Conn: Boehringer Ingelheim Pharmaceuticals; 2007.
28. Narayan P, O'Leary M, Davidai G. Early efficacy of tamsulosin vs terazosin in the treatment of men with benign prostatic hyperplasia: a randomized, open-label trial. J Appl Res. 2005;5:237-245. Available at: http://www.jarcet.com/articles/Vol5Iss2/Narayan.pdf. Accessed June 30, 2008.
29. Cardura XL [package insert]. New York, NY: Pfizer Roerig; 2006.
30. deMey C. Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being [review]. Eur Urol. 1998;34(suppl 2):18-28. doi:10.1159/000052284.
31. Lowe FC. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urol. 1994;44:46-51. doi:10.1016/S0090-4295(94)80008-1.
32. Martell N, Luque M; for HT-BPH Group. Doxazosin added to single-drug therapy in hypertensive patients with benign prostatic hypertrophy. J Clin Hypertens (Greenwich). 2001;3:218-223.
33. Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol. 1995;154:105-109.
34. Lukacs B, Blondin P, MacCarthy C, Du Boys B, Grippon P, Lassale C. Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Eur Urol. 1996;29:29-35.
35. van Kerrebroeck P, Jardin A, Laval KU, van Cangh P; ALFORTI Study Group. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol. 2000;37:306-313. doi: 10.1159/000052361.
36. 1-adrenergic receptors in humans. Naunyn-Schmiedeberg's Arch Pharmacol. 1996;354:557-561.
37. 1-adrenergic receptors. Jpn J Pharmacol. 1999;80:209-215. doi:10.1254/jjp.80.209.
38. 1-adrenoreceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience [review]. Eur Urol. 1996;29:129-144.
39. 1C-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). Br J Urol. 1995;76:325-336.
40. Chapple CR, Baert L, Thind P, Hîfner K, Khoe GSS, Spångberg A; for the European Tamsulosin Study Group. Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). Eur Urol. 1997;32:462-470.
41. Schulman CC, Cortvriend J, Jonas U, Lock TMTW, Vaage S, Speakman MJ; for the European Tamsulosin Study Group. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. Eur Urol. 1999;36:609-620. doi: 10.1159/000020056.
42. Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2003;170(pt 1):498-502.
43. Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther. 1997;19:730-742. doi:10.1016/S0149-2918(97)80097-5.
44. Seidman SN. The aging male: androgens, erectile dysfunction, and depression. J Clin Psychiatry. 2003;64(suppl 10):31-37.
45. Meuleman EJH. Prevalence of erectile dysfunction: need for treatment [review]? Int J Impot Res. 2002;14(suppl 1):S22-S28.
46. Viagra [package insert]. New York, NY: Pfizer Inc; 2007.
47. Levitra [package insert]. West Haven, Conn: Bayer Pharmaceutical Corp; 2007.
48. Cialis [package insert]. Indianapolis, Ind: Lilly ICOS LLC; 2007.
49. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005;31:664-673. doi:10.1016/j.jcrs.2005.02.027.
50. Chang DF. Intraoperative floppy iris syndrome caused by tamsulosin: complication rate on a multicenter prospective study. Abstract presented at: the 2006 ASCRS Symposium, ASOA Congress, and Clinical Surgical Staff Program; March 17-22, 2006; San Francisco, Calif.
51. Man In't Veld AJ, van der Camme TJM, van Loon K. Drug treatment of hypertension in the elderly: the role of alpha-adrenoreceptor blockade [review]. Br J Urol. 1998;81(suppl 1):21-25.
52. Falls among older adults: figures and maps. Centers for Disease Control and Prevention Web site. Available at: http://www.cdc.gov/ncipc/duip/ adultfallsfig-maps.htm. Accessed July 2, 2008.